Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer.

Br J Cancer · 2011 · PMC3137421 · PMID 21654681

Europe PMC DOI

hedged sentence

0.0490

closest p · 1.0× alpha

0.0490

boldest claim

The sentences

of borderline significanceP =0.049actually significant

However, it should be noted that in the ISEL trial, the benefit was of borderline significance (treatment by biomarker interaction test P =0.049; Hirsch et al , 2006 ).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.